Table 4 Cumulative incidence estimates of treatment initiation, transformation to DLBCL before treatment, and death without therapy based on presence or absence of any treatment initiation criteria at diagnosis.

From: Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era

Time from start of W/W

FL status

Likelihood (point estimates) in the next 1 year (95% CI)

Likelihood (point estimates) in the next 2 year (95% CI)

Likelihood (point estimates) in the next 5 year (95% CI)

Likelihood (point estimates) in the next 10 year (95% CI)

Total cohort

Transformation

0.01 (0.00, 0.03)

0.03 (0.01, 0.05)

0.06 (0.04, 0.09)

0.09 (0.06, 0.13)

Therapy

0.16 (0.13, 0.20)

0.26 (0.22, 0.31)

0.43 (0.38, 0.48)

0.48 (0.43, 0.54)

Death

0.01 (0.00, 0.03)

0.02 (0.01, 0.04)

0.04 (0.03, 0.07)

0.06 (0.04, 0.10)

Any treatment initiation criteria: positive

Transformation

0.01 (0.00, 0.04)

0.02 (0.01, 0.06)

0.06 (0.04, 0.11)

0.12 (0.07, 0.19)

Therapy

0.15 (0.11, 0.21)

0.27 (0.22, 0.34)

0.44 (0.37, 0.51)

0.48 (0.42, 0.56)

Death

0.01 (0.00, 0.04)

0.02 (0.01, 0.05)

0.03 (0.02, 0.07)

0.06 (0.03, 0.12)

Any treatment initiation criteria: negative

Transformation

0.01 (0.00, 0.04)

0.03 (0.01, 0.07)

0.06 (0.03, 0.11)

0.06 (0.03, 0.11)

Therapy

0.15 (0.11, 0.21)

0.24 (0.18, 0.31)

0.42 (0.35, 0.50)

0.49 (0.42, 0.57)

Death

0.01 (0.00, 0.04)

0.03 (0.01, 0.07)

0.05 (0.03, 0.10)

0.06 (0.03, 0.12)